Pre-made Lifastuzumab benchmark antibody ( Whole mAb ADC, anti-SLC34A2 therapeutic antibody, Anti-NAPI-3B/NAPI-IIb/NPTIIb/PULAM Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Lifastuzumab biosimilar, Whole mAb ADC, Anti-SLC34A2 Antibody: Anti-NAPI-3B/NAPI-IIb/NPTIIb/PULAM therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Lifastuzumab vedotin, also known as DNIB0600A and RG-7599, is a novel antibody-drug conjugate being developed by Genentech/Roche, in clinical trials. The investigational drug is being compared to pegylated liposomal doxorubicin for the treatment of patients with platinum-resistant ovarian cancer.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-311-1mg	1mg	4635
GMP-Bios-ab-311-10mg	10mg	Inquiry
GMP-Bios-ab-311-100mg	100mg	Inquiry
GMP-Bios-ab-311-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Lifastuzumab biosimilar, Whole mAb ADC, Anti-SLC34A2 Antibody: Anti-NAPI-3B/NAPI-IIb/NPTIIb/PULAM therapeutic antibody
INN Name	Lifastuzumab
Target	SLC34A2
Format	Whole mAb ADC
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2013
Year Recommended	2014
Companies	Genentech
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Fallopian tube cancer;Non-small cell lung cancer;Ovarian cancer;Peritoneal cancer
Development Tech	na